On November 3, 2025, Johnson & Johnson MedTech, a recognized global leader in cardiac arrhythmia management, announced a major showcase of its latest clinical innovations in pulsed field ablation (PFA) during the Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) joint annual meeting scheduled to occur in Yokohama, Japan between November 12 and 15, 2025. This event is an authoritative platform for cardiology and electrophysiology professionals throughout Asia Pacific, gathering industry leaders, clinicians, and facility managers to examine emerging techniques, breakthrough technologies, and actionable clinical data that may shape hospital procurement and treatment decisions across the region.

The centerpiece of Johnson & Johnson MedTech's presence is its integrated VARIPULSE™ Platform for atrial fibrillation (AF) ablation procedures, which includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and the CARTO™ 3 Mapping System with VARIPULSE™ Software. The platform has now achieved approval across an extensive global footprint, encompassing the United States, Europe, Asia Pacific, Canada, and Latin America, and has been utilized in more than 25,000 clinical procedures worldwide including operations in Japan, Hong Kong, Mainland China, Korea, Taiwan, and Australia.

Key presentations at the congress will spotlight new clinical studies and real-world experience data that address critical factors such as patient safety, efficacy in arrhythmia treatment, and enhanced workflow optimization. According to Johnson & Johnson MedTech, the latest evidence underscores not only advancements in safety and efficacy profiles of pulsed field ablation technology, but also procedural consistency and efficiency enhancements that support high-volume clinical environments. These data points are particularly relevant for hospital administrators, cardiac program directors, and procurement specialists seeking reliable, scalable solutions to improve clinical outcomes in AF—a leading contributor to stroke risk and hospitalizations in the aging Asian population.

Strategically, the broad regional approval and favorable outcomes support the platform’s fit for diverse healthcare settings within Asia, facilitating cross-border harmonization of clinical protocols, and reinforcing the market positioning of facilities equipped with state-of-the-art arrhythmia intervention technology. Technological integration with widely adopted electrophysiology mapping and navigation software offers additional workflow benefits for both clinicians and operational managers, enabling optimized patient throughput and supporting hospitals' clinical excellence goals.

The APHRS/JPHRS meeting is a central venue for industry and health system collaboration, knowledge exchange, and professional education, expected to influence procurement and deployment strategies for cardiac care technology in leading hospitals across Asia-Pacific for the coming years. Johnson & Johnson MedTech's leadership and ongoing investment in clinical validation signal their commitment to supporting hospitals in the region as they address the rising prevalence and complexity of atrial fibrillation within Asian patient populations, and as they invest in next-generation tools to compete on both quality and operational efficiency.

In summary, this announcement reflects not only product innovation but also the growing sophistication of hospital procurement in the Asia-Pacific landscape, where clinical data, operational consistency, and scalable technology ecosystems are increasingly central to strategic investment in advanced cardiac care.